Literature DB >> 14749922

Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase.

Jeong-Hee Choi1, Hae-Sim Park, Heung-Bum Oh, June-Hyuk Lee, Yu-Jin Suh, Choon-Sik Park, Hyoung-Doo Shin.   

Abstract

A recent study has demonstrated the possible involvement of a leukotriene C4 synthase (LTC4S) gene polymorphism in ASA-intolerant asthma (AIA) in a Polish population, whereas no significant association was noted in other populations. To investigate the role of genetic polymorphism in AIA development, we screened single nucleotide polymorphisms (SNPs) of the key enzymes involved in arachidonate metabolism, and the cysteinyl leukotriene receptor 1 (CYSLTR1) in a large Korean population with AIA: 93 AIA and 181 ASA-tolerant asthma (ATA) patients, and 123 normal controls. The single-base extension method was used to genotype SNPs in 5-lipoxygenase (ALOX5, -1708G-->A, 21C-->T, 270G-->A, 1728G-->A), ALOX5-activating protein (ALOX5AP, 218A-->G), prostaglandin-endoperoxide synthase 2 (PTGS2, COX2, -162C-->G, 10T-->G, R228H, V511A), LTC4S (-444A-->C), and CYSLTR1 (927T-->C). Haplotype analyses were undertaken for the SNPs in ALOX5. No significant differences in allele and genotype frequencies of single SNPs were observed between the patient groups ( P>0.05). However, the frequency of the ALOX5-ht1[G-C-G-A] haplotype in the AIA group was significantly higher than its frequency in the ATA group with a probability ( P) of 0.01, odds ratio (OR) of 5.0, and 95% confidence interval (95%CI) of 1.54-17.9, and in the normal controls ( P=0.03, OR=4.5, 95%CI=1.1-18.4), by using a dominant model. These results suggest a lack of association between the ALOX5AP, PTGS2, LTC4S, and CYSLTR1 gene polymorphisms and the AIA phenotype in the Korean population. However, the possible involvement of ALOX5-ht1[G-C-G-A] in AIA development is suggested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749922     DOI: 10.1007/s00439-004-1082-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  31 in total

Review 1.  Treatment of asthma with drugs modifying the leukotriene pathway.

Authors:  J M Drazen; E Israel; P M O'Byrne
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

2.  Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.

Authors:  M Sanak; H U Simon; A Szczeklik
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

3.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 4.  The cyclooxygenase theory of aspirin-induced asthma.

Authors:  A Szczeklik
Journal:  Eur Respir J       Date:  1990-05       Impact factor: 16.671

5.  Concerning the nature of intolerance to aspirin.

Authors:  M Samter; R F Beers
Journal:  J Allergy       Date:  1967-11

6.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

7.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

Review 8.  Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.

Authors:  Andrew Szczeklik; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

Review 9.  The role of leukotrienes in inflammation.

Authors:  W R Henderson
Journal:  Ann Intern Med       Date:  1994-11-01       Impact factor: 25.391

10.  Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma.

Authors:  Yukio Kawagishi; Haruhisa Mita; Masami Taniguchi; Muneharu Maruyama; Rokuo Oosaki; Noritaka Higashi; Tatsuhiko Kashii; Masashi Kobayashi; Kazuo Akiyama
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793

View more
  31 in total

Review 1.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

2.  Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.

Authors:  H S Chang; S W Shin; T H Lee; D J Bae; J S Park; Y H Kim; S T Uh; B W Choi; M K Kim; I S Choi; B L Park; H D Shin; C S Park
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

3.  Association of FANCC polymorphisms with FEV1 decline in aspirin exacerbated respiratory disease.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Charisse Flerida A Pasaje; Joon Seol Bae; Jong Sook Park; Sung Woo Park; Soo-Taek Uh; Jae-Sung Choi; Yong-Hoon Kim; Mi-Kyeong Kim; Inseon S Choi; Sang Heon Cho; Byoung Whui Choi; Choon-Sik Park; Hyoung Doo Shin
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

4.  Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors.

Authors:  W Liu; E M Poole; C M Ulrich; R J Kulmacz
Journal:  Pharmacogenomics J       Date:  2010-06-15       Impact factor: 3.550

5.  Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma.

Authors:  Mitsuteru Akahoshi; Kazuhiko Obara; Tomomitsu Hirota; Akira Matsuda; Koichi Hasegawa; Naomi Takahashi; Makiko Shimizu; Kazuko Nakashima; Lei Cheng; Satoru Doi; Hiroshi Fujiwara; Akihiko Miyatake; Kimie Fujita; Noritaka Higashi; Masami Taniguchi; Tadao Enomoto; Xiao-Quan Mao; Hitoshi Nakashima; Chaker N Adra; Yusuke Nakamura; Mayumi Tamari; Taro Shirakawa
Journal:  Hum Genet       Date:  2005-04-02       Impact factor: 4.132

Review 6.  Genetics and pharmacogenetics of the leukotriene pathway.

Authors:  Kelan G Tantisira; Jeffrey M Drazen
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

Review 7.  G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Authors:  Miles D Thompson; Jun Takasaki; Valérie Capra; G Enrico Rovati; Kathy A Siminovitch; W McIntyre Burnham; Thomas J Hudson; Yohan Bossé; David E C Cole
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population.

Authors:  Seung-Hyun Kim; Jeong-Hee Choi; J W Holloway; Chang-Hee Suh; Dong-Ho Nahm; Eun-Ho Ha; Choon-Sik Park; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

9.  Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Hyun Sub Cheong; Joon Seol Bae; Jong Sook Park; An Soo Jang; Soo-Taek Uh; Jae-Sung Choi; Yong-Hoon Kim; Mi-Kyeong Kim; Inseon S Choi; Sang Heon Cho; Byoung Whui Choi; Choon-Sik Park; Hyoung Doo Shin
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

10.  The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos.

Authors:  M Via; A De Giacomo; H Corvol; C Eng; M A Seibold; C Gillett; J Galanter; S Sen; H Tcheurekdjian; R Chapela; J R Rodríguez-Santana; W Rodríguez-Cintrón; S Thyne; P C Avila; S Choudhry; E González Burchard
Journal:  Clin Exp Allergy       Date:  2010-01-11       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.